Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial
Theodore W. Laetsch(Children's Hospital of Philadelphia), Andrew C. Harris(Primary Children's Hospital), Hidefumi Hiramatsu(Kyoto University), Christina Peters(Cancer Research Institute of the Slovak Academy of Sciences), Françoise Méchinaud(Hotel Dieu Hospital), Gary Douglas Myers(Baylor College of Medicine), Susana Rives(Hospital Sant Joan de Déu Barcelona), Peter Bader(Goethe University Frankfurt), Eneida R. Nemecek(Oregon Health & Science University), Jochen Buechner(Oslo University Hospital), Lawrence Rasouliyan, Heather E. Stefanski(National Marrow Donor Program), Barbara De Moerloose(Ghent University Hospital), Himalee S. Sabnis(Emory University), Nicolas Boissel(Inserm), Stephan A. Grupp(Children's Hospital of Philadelphia), Gregory A. Yanik(University of Michigan), Timothy Driscoll(Institut Pasteur), Henrique Bittencourt(Centre Hospitalier Universitaire Sainte-Justine), André Baruchel(Hôpital Robert-Debré), Andrew C. Dietz(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Sweta Shah(Novartis (United States)), Lan Yi(Unknown), Michael A. Pulsipher(Primary Children's Hospital), Jie Zhang(Hefei University of Technology), Kara L. Davis(Stanford Medicine)
Cited by 90
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795